Two sides to every story: The HIF-dependent and HIF-independent functions of pVHL

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 2, 2011, Pages 187-195

  Li, Mingqing ^a   Kim, William Y ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Cilia; HIF; Hypoxia inducible factor; Pheochromocytoma; PVHL; Renal cell carcinoma; Senescence; Tumorigenesis; Von Hippel Lindau

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

AGING; ANIMAL; APOPTOSIS; EUKARYOTIC FLAGELLUM; EXTRACELLULAR MATRIX; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MICROTUBULE; MOUSE; REVIEW; VON HIPPEL LINDAU DISEASE;

AGING; ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CILIA; EXTRACELLULAR MATRIX; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; KIDNEY NEOPLASMS; MICE; MICROTUBULES; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EUKARYOTA;

EID: 79951868152     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01238.x     Document Type: Review

References (100)

1. Collins E. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalmol Soc UK. 1894; 14: 141-9.
2. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004; 22: 4991-5004.
3. Seizinger BR, Rouleau GA, Ozelius LJ, et al Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988; 332: 268-9.
4. Latif F, Tory K, Gnarra J, et al Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993; 260: 1317-20.
5. Schoenfeld A, Davidowitz EJ, Burk RD. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA. 1998; 95: 8817-22.
6. Iliopoulos O, Ohh M, Kaelin WG Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA. 1998; 95: 11661-6.
7. Blankenship C, Naglich JG, Whaley JM, et al Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene. 1999; 18: 1529-35.
8. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nature Rev. 2002; 2: 673-82.
9. Lee S, Neumann M, Stearman R, et al Transcription-dependent nuclear-cytoplas-mic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol. 1999; 19: 1486-97.
10. Lee S, Chen DY, Humphrey JS, et al Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci USA. 1996; 93: 1770-5.
11. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 2001; 13: 167-71.
12. Sang N, Fang J, Srinivas V, et al Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol. 2002; 22: 2984-92.
13. Iyer NV, Kotch LE, Agani F, et al Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998; 12: 149-62.
14. Tian H, Hammer RE, Matsumoto AM, et al The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 1998; 12: 3320-4.
15. Compernolle V, Brusselmans K, Acker T, et al Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 2002; 8: 702-10.
16. Gruber M, Hu CJ, Johnson RS, et al Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci USA. 2007; 104: 2301-6.
17. Wang V, Davis DA, Haque M, et al Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res. 2005; 65: 3299-306.
18. Raval RR, Lau KW, Tran MG, et al Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005; 25: 5675-86.
19. Kim WY, Safran M, Buckley MR, et al Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J. 2006; 25: 4650-62.
20. Hu CJ, Sataur A, Wang L, et al The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol Cell. 2007; 18: 4528-42.
21. Hu CJ, Wang LY, Chodosh LA, et al Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003; 23: 9361-74.
22. Maynard MA, Qi H, Chung J, et al Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem. 2003; 278: 11032-40.
23. Maynard MA, Evans AJ, Hosomi T, et al Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J. 2005; 19: 1396-406.
24. Makino Y, Kanopka A, Wilson WJ, et al Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem. 2002; 277: 32405-8.
25. Makino Y, Cao R, Svensson K, et al Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature. 2001; 414: 550-4.
26. Jaakkola P, Mole DR, Tian YM, et al Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292: 468-72.
27. Ivan M, Kondo K, Yang H, et al HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001; 292: 464-8.
28. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001; 294: 1337-40.
29. Yu F, White SB, Zhao Q, et al Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer Res. 2001; 61: 4136-42.
30. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008; 30: 393-402.
31. Berra E, Richard DE, Gothie E, et al HIF-1-dependent transcriptional activity is required for oxygen- mediated HIF-1alpha degradation. FEBS Lett. 2001; 491: 85-90.
32. Bishop T, Gallagher D, Pascual A, et al Abnormal sympathoadrenal development and systemic hypotension in PHD3-/-mice. Mol Cell Biol. 2008; 28: 3386-400.
33. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nature Rev. 2008; 8: 865-73.
34. Yu F, White SB, Zhao Q, et al HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA. 2001; 98: 9630-5.
35. Masson N, Willam C, Maxwell PH, et al Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 2001; 20: 5197-206.
36. Hewitson KS, McNeill LA, Riordan MV, et al Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 2002; 277: 26351-5.
37. Lando D, Peet DJ, Gorman JJ, et al FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002; 16: 1466-71.
38. Dayan F, Roux D, Brahimi-Horn MC, et al The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res. 2006; 66: 3688-98.
39. Yan Q, Bartz S, Mao M, et al The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol. 2007; 27: 2092-102.
40. Maxwell PH, Wiesener MS, Chang GW, et al The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399: 271-5.
41. Gordan JD, Lal P, Dondeti VR, et al HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008; 14: 435-46.
42. Mandriota KT, DR Davies, PG Murray, et al Hif activation identifies early lesion in vhl kidneys: evidence for site-specific tumor suppressor funciton in the nephron. Cancer Cell. 2002; 1: 459-68.
43. Dalgliesh GL, Furge K, Greenman C, et al Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010; 463: 360-3.
44. Zimmer M, Doucette D, Siddiqui N, et al Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res. 2004; 2: 89-95.
45. Kondo K, Kim WY, Lechpammer M, et al Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003; 1: E83.
46. Kondo K, Klco J, Nakamura E, et al Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002; 1: 237-46.
47. Maranchie JK, Vasselli JR, Riss J, et al The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 2002; 1: 247-55.
48. Haase VH, Glickman JN, Socolovsky M, et al Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA. 2001; 98: 1583-8.
49. Rankin EB, Higgins DF, Walisser JA, et al Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol. 2005; 25: 3163-72.
50. Bracken CP, Fedele AO, Linke S, et al Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment. J Biol Chem. 2006; 281: 22575-85.
51. Gordan JD, Bertout JA, Hu CJ, et al HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007; 11: 335-47.
52. Beroukhim R, Brunet JP, Di Napoli A, et al Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009; 69: 4674-81.
53. Semenza GL. Targeting HIF-1 for cancer therapy. Nature Rev. 2003; 3: 721-32.
54. Jiang Y, Zhang W, Kondo K, et al Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res. 2003; 1: 453-62.
55. Zatyka M, da Silva NF, Clifford SC, et al Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel- Lindau disease. Cancer Res. 2002; 62: 3803-11.
56. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108: 153-64.
57. Vasavada SP, Novick AC, Williams BR. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology. 1998; 51: 1057-61.
58. Tomasino RM, Morello V, Tralongo V, et al p53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization. Pathologica. 1994; 86: 227-33.
59. Sanchez-Puig N, Veprintsev DB, Fersht AR. Binding of natively unfolded HIF-1alpha ODD domain to p53. Mol Cell. 2005; 17: 11-21.
60. An WG, Kanekal M, Simon MC, et al Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature. 1998; 392: 405-8.
61. Sendoel A, Kohler I, Fellmann C, et al HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature. 2010; 465: 577-83.
62. Roe JS, Kim H, Lee SM, et al p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell. 2006; 22: 395-405.
63. Oya M, Ohtsubo M, Takayanagi A, et al Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene. 2001; 20: 3888-96.
64. Qi H, Ohh M. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent anti-apoptotic pathway. Cancer Res. 2003; 63: 7076-80.
65. An J, Rettig MB. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol. 2005; 25: 7546-56.
66. Pantuck AJ, An J, Liu H, et al NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. Cancer Res. 2010; 70: 752-61.
67. Yang H, Minamishima YA, Yan Q, et al pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell. 2007; 28: 15-27.
68. Kim WY, Kaelin WG Jr. Molecular pathways in renal cell carcinoma-rationale for targeted treatment. Semin Oncol. 2006; 33: 588-95.
69. Neumann HP, Bausch B, McWhinney SR, et al Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002; 346: 1459-66.
70. Clifford SC, Cockman ME, Smallwood AC, et al Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 2001; 10: 1029-38.
71. Hoffman MA, Ohh M, Yang H, et al von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001; 10: 1019-27.
72. Lee S, Nakamura E, Yang H, et al Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005; 8: 155-67.
73. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8: 729-40.
74. Kim WY, Sharpless NE. VHL inactivation: a new road to senescence. Cancer Cell. 2008; 13: 295-7.
75. Parrinello S, Samper E, Krtolica A, et al Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol. 2003; 5: 741-7.
76. Welford SM, Bedogni B, Gradin K, et al HIF1alpha delays premature senescence through the activation of MIF. Genes Dev. 2006; 20: 3366-71.
77. Bell EL, Klimova TA, Eisenbart J, et al Mitochondrial reactive oxygen species trigger hypoxia-inducible factor-dependent extension of the replicative life span during hypoxia. Mol Cell Biol. 2007; 27: 5737-45.
78. Young AP, Schlisio S, Minamishima YA, et al VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 2008; 10: 361-9.
79. Welford SM, Dorie MJ, Li X, et al Renal oxygenation suppresses VHL-loss-induced senescence that is caused by increased sensitivity to oxidative stress. Mol Cell Biol. 2010; 30: 4595-603.
80. Hergovich A, Lisztwan J, Barry R, et al Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol. 2003; 5: 64-70.
81. Singla V, Reiter JF. The primary cilium as the cell's antenna: signaling at a sensory organelle. Science. 2006; 313: 629-33.
82. Zhuang Z, Roth MJ, Emmert-Buck MR, et al Detection of the von Hippel-Lindau gene deletion in cytologic specimens using microdissection and the polymerase chain reaction. Acta Cytol. 1994; 38: 671-5.
83. Lubensky IA, Gnarra JR, Bertheau P, et al Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol. 1996; 149: 2089-94.
84. Siroky BJ, Guay-Woodford LM. Renal cystic disease: the role of the primary cilium/centrosome complex in pathogenesis. Adv Chronic Kidney Dis. 2006; 13: 131-7.
85. Hergovich A, Lisztwan J, Thoma CR, et al Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Mol Cell Biol. 2006; 26: 5784-96.
86. Lutz MS, Burk RD. Primary cilium formation requires von hippel-lindau gene function in renal-derived cells. Cancer Res. 2006; 66: 6903-7.
87. Esteban MA, Tran MG, Harten SK, et al Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 2006; 66: 3567-75.
88. Frew IJ, Thoma CR, Georgiev S, et al pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J. 2008; 27: 1747-57.
89. Bonsib SM. Renal cystic diseases and renal neoplasms: a mini-review. Clin J Am Soc Nephrol. 2009; 4: 1998-2007.
90. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001; 2: 285-93.
91. Kurban G, Duplan E, Ramlal N, et al Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. Oncogene. 2008; 27: 1004-12.
92. Tang N, Mack F, Haase VH, et al pVHL function is essential for endothelial extra-cellular matrix deposition. Mol Cell Biol. 2006; 26: 2519-30.
93. Ohh M, Yauch RL, Lonergan KM, et al The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998; 1: 959-68.
94. Bishop T, Lau KW, Epstein AC, et al Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol. 2004; 2: e289.
95. Russell RC, Ohh M. NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHL. EMBO Rep. 2008; 9: 486-91.
96. Stickle NH, Chung J, Klco JM, et al pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol. 2004; 24: 3251-61.
97. Calzada MJ, Esteban MA, Feijoo-Cuaresma M, et al von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res. 2006; 66: 1553-60.
98. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. 2005; 5: 689-98.
99. Turcotte S, Chan DA, Sutphin PD, et al A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell. 2008; 14: 90-102.
100. Bommi-Reddy A, Almeciga I, Sawyer J, et al Kinase requirements in human cells: III. Altered kinase requirements in VHL-/-cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA. 2008; 105: 16484-9.